Trials / Completed
CompletedNCT01447706
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
A Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 223 (actual)
- Sponsor
- Merrimack Pharmaceuticals · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine whether the combination of MM-121 plus paclitaxel is more effective than paclitaxel alone
Detailed description
This is a multicenter, open-label, randomized, Phase II study of MM-121 in patients with platinum resistant or refractory recurrent/advanced ovarian cancers. Up to 210 patients will be randomized (2:1) to receive MM-121 plus paclitaxel or paclitaxel alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MM-121 | MM-121 (SAR256212) (IV) |
| DRUG | Paclitaxel | Standard dosing Paclitaxel (IV) |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2013-09-01
- Completion
- 2015-06-01
- First posted
- 2011-10-06
- Last updated
- 2016-05-12
- Results posted
- 2016-05-12
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01447706. Inclusion in this directory is not an endorsement.